Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage ...

Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Hidradenitis Suppurativa.

Happy birthday to the world's first ever mirrorless camera, which just turned 16 years old! But is it still usable in 2024?

Similarly, H.C. Wainwright adjusted its outlook on G1 Therapeutics, reducing the price target on the stock, while still maintaining a Buy rating. In terms of clinical trials, the company's Phase 3 ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Researchers from the University of Alabama at Birmingham have identified a promising new combination therapy for metastatic ...

This sequential expression followed the phases of the traditional cell cycle: G0/G1 (the cell grows larger), S (the cell ... without a distinct transcriptional change going from the S phase into the ...